Equities analysts predict that Amdocs Limited (NASDAQ:DOX) will post sales of $1.03 billion for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Amdocs’ earnings, with the highest sales estimate coming in at $1.03 billion and the lowest estimate coming in at $1.02 billion. Amdocs reported sales of $1.00 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 3%. The company is expected to report its next earnings results on Tuesday, July 30th.
According to Zacks, analysts expect that Amdocs will report full-year sales of $4.09 billion for the current year, with estimates ranging from $4.08 billion to $4.10 billion. For the next fiscal year, analysts forecast that the company will post sales of $4.21 billion, with estimates ranging from $4.19 billion to $4.24 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Amdocs.
Amdocs (NASDAQ:DOX) last issued its earnings results on Tuesday, May 14th. The technology company reported $1.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.03. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.02 billion. Amdocs had a net margin of 8.96% and a return on equity of 15.18%. Amdocs’s revenue was up 2.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.95 earnings per share.
Hedge funds have recently made changes to their positions in the company. Morgan Dempsey Capital Management LLC bought a new stake in shares of Amdocs during the 4th quarter valued at $25,000. Riverview Trust Co bought a new stake in shares of Amdocs during the 4th quarter valued at $27,000. Meeder Asset Management Inc. boosted its holdings in shares of Amdocs by 47.8% during the 1st quarter. Meeder Asset Management Inc. now owns 1,057 shares of the technology company’s stock valued at $57,000 after buying an additional 342 shares in the last quarter. Blue Sky Asset Management LLC bought a new stake in shares of Amdocs during the 1st quarter valued at $103,000. Finally, Private Capital Group LLC boosted its holdings in shares of Amdocs by 99.8% during the 1st quarter. Private Capital Group LLC now owns 1,990 shares of the technology company’s stock valued at $108,000 after buying an additional 994 shares in the last quarter. Institutional investors own 91.54% of the company’s stock.
NASDAQ DOX traded down $0.02 on Wednesday, hitting $62.88. 961,041 shares of the company were exchanged, compared to its average volume of 1,022,008. The stock has a market capitalization of $8.81 billion, a P/E ratio of 16.82, a PEG ratio of 1.85 and a beta of 0.42. Amdocs has a 12 month low of $52.60 and a 12 month high of $69.16. The stock’s fifty day moving average is $61.35.
The company also recently announced a quarterly dividend, which will be paid on Friday, July 19th. Stockholders of record on Friday, June 28th will be issued a $0.285 dividend. The ex-dividend date of this dividend is Thursday, June 27th. This represents a $1.14 annualized dividend and a dividend yield of 1.81%. Amdocs’s dividend payout ratio is currently 30.48%.
Amdocs Company Profile
Amdocs Limited, through its subsidiaries, provides software and services to the communications, pay TV, entertainment, and media industry service providers worldwide. The company offers amdocsONE a line of services designed for various stages of a service provider's lifecycle, including planning, delivery, implementation, and ongoing support, as well as consumer experience and monetization, media and digital, enterprise and connected society, service-driven network, and services and agile operation solutions.
Featured Article: Moving Average – How it Helps Investors in Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.